# A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.

> **NCT00502840** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 193 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** rituximab [MabThera/Rituxan]

## Key facts

- **NCT ID:** NCT00502840
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07-23
- **Primary completion:** 2011-09-20
- **Final completion:** 2011-09-20
- **Target enrollment:** 193 (ACTUAL)
- **Last updated:** 2017-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00502840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00502840, "A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00502840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*